NCT02774707|Unknown
Loading search results
Sponsor study identifier
observational
100
1 country
1
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Human autologous serum is commonly used in the treatment of dry eye disease. However, different patients may have different effect with autologous serum treatment. We would like to find if different autologous serum had different component of cytokines in different etiologies of dry eye.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
January 10, 2016
Actual (reported)May 17, 2016
Actual (reported)January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Epidermal growth factor concentration in human autologous serum from different etiologies of dry eye
We would measure Epidermal growth factor concentration (ng/ml) by ELISA according to the manufactures instruction. We plan to collect 40 patients from different groups.
1 year
Transforming growth factor beta (ng/ml) concentration in human autologous serum from different etiologies of dry eye
We would measure Transforming growth factor beta (ng/ml) by ELISA according to the manufactures instruction. We plan to collect 40 patients from different groups.
1 year
Fibronectin (ug/ml) concentration in human autologous serum from different etiologies of dry eye
We would measureFibronectin (ug/ml) concentration by ELISA according to the manufactures instruction. We plan to collect 40 patients from different groups.
1 year
Hyaluronic acid (ug/ml) concentration in human autologous serum from different etiologies of dry eye
We would measure Hyaluronic acid (ug/ml) concentration by ELISA according to the manufactures instruction. We plan to collect 40 patients from different groups.
1 year
1. Patients who need autologous human serum as treatment of dry eye disease 2. Healthy volunteers
National Taiwan University Hospital
Taipei, Taiwan
Wei-Li Chen
ational Taiwan University Hospital, Ophthalmology Department
First Submitted
January 10, 2016
First Posted
May 17, 2016
Study Start
January 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2017
Estimated (date passed)Allogeneic Versus Autologous Serum Eye Drops
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 8, 2016
Record last verified: 2016-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: